They can't predict sales volumes. They might have an idea but that is asking for trouble if they inform the market of the "guestimate" and it turns out to be significantly variant - either way. Chiesi are a big company and should be able to do the successful commercialisation of the Bronchitol - which will be significantly beneficial to PXS.
